Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
MEDICIS PHARMACEUTICAL CORP (MRX)
|
Add to portfolio |
|
|
|
| Price: |
$36.62
| | Metrics |
| OS: |
58.9
|
M
| |
10
|
% ROE
|
| Market cap: |
$2.16
|
B
| |
9
|
% ROIC
|
|
Net cash:
|
$178
|
M
| |
$3.02
|
per share
|
|
EV:
|
$1.98
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$180
|
M
| |
11.0
|
x EV/EBITDA
|
|
EBIT
|
$115
|
M
| |
17.2
|
x EV/EBIT
|
| EPS |
$1.73
| |
21.2
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Jun-30-05 | Jun-30-04 |
| Revenues | 721.1 | 695.9 | 570.6 | 517.8 | 457.4 | 393.2 | 365.7 | 303.7 |
| Revenue growth | 3.6% | 22.0% | 10.2% | 13.2% | 16.3% | | 20.4% | 22.7% |
| Cost of goods sold | 66.9 | 66.9 | 56.1 | 38.7 | 56.1 | 46.1 | 58.1 | 46.6 |
| Gross profit | 654.2 | 629.1 | 514.6 | 479.0 | 401.3 | 347.1 | 307.5 | 257.1 |
| Gross margin | 90.7% | 90.4% | 90.2% | 92.5% | 87.7% | 88.3% | 84.1% | 84.7% |
| Selling, general and administrative | 353.4 | 305.0 | 266.9 | 279.3 | 242.6 | 202.5 | 130.9 | 118.3 |
| Research and development | 100.1 | 69.0 | 83.2 | 100.4 | 39.4 | 161.8 | 65.7 | 16.5 |
| EBITA | 225.0 | 273.0 | 183.6 | 71.7 | 94.7 | -40.3 | 88.6 | 105.6 |
| EBITA margin | 31.2% | 39.2% | 32.2% | 13.8% | 20.7% | -10.2% | 24.2% | 34.8% |
| Amortization of intangibles | 25.1 | 21.3 | 22.0 | | | | | |
| EBIT | 199.9 | 251.7 | 161.6 | 71.7 | 94.7 | -40.3 | 88.6 | 105.6 |
| EBIT margin | 27.7% | 36.2% | 28.3% | 13.8% | 20.7% | -10.2% | 24.2% | 34.8% |
| Pre-tax income | 183.2 | 249.0 | 165.9 | 42.4 | 119.0 | -72.7 | 89.4 | 46.2 |
| Income taxes | 76.2 | 98.6 | 71.2 | 32.1 | 48.5 | -24.6 | 31.0 | 15.3 |
| Tax rate | 41.6% | 39.6% | 42.9% | 75.8% | 40.8% | 33.8% | 34.7% | 33.2% |
| Earnings from continuing ops | 142.2 | 92.5 | 54.8 | 10.3 | 70.4 | -48.2 | 58.4 | 30.8 |
| Earnings from discontinued ops | -19.6 | 27.0 | 18.8 | | | | | |
| Net income | 122.6 | 119.5 | 73.6 | 10.3 | 70.4 | -48.2 | 58.4 | 30.8 |
| Net margin | 17.0% | 17.2% | 12.9% | 2.0% | 15.4% | -12.2% | 16.0% | 10.2% |
| |
| Diluted EPS | $2.13 | $1.43 | $0.87 | $0.18 | $0.99 | ($0.88) | $0.82 | $0.43 |
| Shares outstanding (diluted) | 66.8 | 64.6 | 63.2 | 56.6 | 71.2 | 54.7 | 70.9 | 72.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|